PURPOSE: To determine in a prospective study the efficacy, @entity137 , and long-term outcome of up-front allogeneic stem-cell transplantation (allo- @entity12497 ) in @entity1582 ( @entity1582 ). @entity1 AND METHODS: In the prospective phase III study by the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), HOVON 24 @entity1582 , 53 @entity1 with an HLA-identical sibling (median age at transplantation, 48 years; range, 31 to 56 years) were allocated to a partial T-cell-depleted allo- @entity12497 after induction therapy. RESULTS: The overall response rate after allo- @entity12497 was 89% (47 of 53 @entity1 ), including the 19% of @entity1 (10 of 53 @entity1 ) with a complete remission (CR). Five @entity1 achieved a CR only after allo- @entity12497 . Five (71%) of seven primary refractory @entity1 obtained a response to allo- @entity12497 , all of whom had a partial remission. With a median follow-up of 38 months (range, 25 to 61 months), 20 @entity1 are alive since allo- @entity12497 and 33 @entity1 have died (14 from progressive disease, 18 from treatment-related mortality [TRM], and one from another cause). Occurrence of @entity2132 grades 2 to 4 predicted for higher TRM in a time-dependent analysis. The median progression-free survival time after allo- @entity12497 was 17 months. Median overall survival time after allo- @entity12497 was 25 months, or 29 months from the start of therapy. Only three @entity1 are in continuing CR, indicating that the potential cure rate of this approach is, at best, 6%. CONCLUSION: This first prospective evaluation of up-front allo- @entity12497 of @entity1582 in a multicenter setting does not support the use of T-cell-depleted myeloablative allo- @entity12497 as part of first-line therapy.

Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of @entity1582 : a prospective evaluation of @entity1 treated in the phase III study HOVON 24 XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity12497 :: ('MESH:C535780', 'Disease') :: ['SCT'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'MM'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['acute graft-versus-host disease']
@entity1582 :: (MESH:D009101,Disease) :: ['MM']
